Crossmark

Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy

Crossref DOI link: https://doi.org/10.1007/s11060-024-04689-0

Published Online: 2024-04-23

Published Print: 2024-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sun, Ting

Liu, Bin

Cai, Lize

Zhou, Youxin

Yang, Wei

Li, Yanyan
License Information

Text and Data Mining valid from 2024-04-23

Version of Record valid from 2024-04-23
More Information

Article History

Received: 18 March 2024

Accepted: 18 April 2024

First Online: 23 April 2024

Declarations

:

: This present study was conducted in compliance with the principles of the Institutional Animal Care and Use Committee at the first Affiliated Hospital of Soochow University. Approval was obtained from the Ethics Committee of the first Affiliated Hospital of Soochow University.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below